Phase 2 data for novel oral small molecule, HRS-5346

The novel oral small molecule inhibitor of Lp(a) particle assembly, HRS-5346, reduces Lp(a) levels in patients at high cardiovascular risk and with Lp(a) ≥150 nmol/L and is generally well tolerated, according to Phase 2 data presented by Dr Dan Zhu, from Peking University Third Hospital, Beijing, China.